Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).
Offering enhanced sensitivity and spatial resolution capability approaching that of positron emission tomography (PET), the AnyScan Trio SPECT/CT TheraMax system was introduced at the European Association of Nuclear Medicine (EANM) annual conference in Hamburg, Germany.
Designed with an emphasis on targeted radionuclide therapy applications, the AnyScan Trio SPECT/CT TheraMax platform includes detectors and collimators that enable the use of alpha- and beta-emitting radiopharmaceuticals as well as high-energy gamma photons such as lutetium-177 (177Lu) and actinium-225 (225Ac), according to Mediso, the manufacturer of the AnyScan Trio SPECT/CT TheraMax device.
Recently installed at the University Hospital Regensburg in Regensburg, Germany, the AnyScan Trio SPECT/CT TheraMax system was designed with an emphasis on targeted radionuclide therapy applications, according to Mediso, the manufacturer of the system. (Photo courtesy of Mediso.)
The company noted that other features and capabilities of the system include:
• surface detectors up to five times larger than those utilized in 12-detector cadmium zinc telluride (CZT) platforms;
• PET-like image quality with bolstered spatial resolution facilitated by the platform’s high-density sensor arrangement;
• whole-body SPECT/CT scans with up to 300 percent higher sensitivity in comparison to conventional dual-detector devices; and
• integrated computed tomography (CT) options for low-dose, ultra-low dose and “zero-dose” protocols with artificial intelligence (AI)-enabled SyCT (Synthetic CT).
"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT," said Istvan Bagaméry, the managing director of Mediso. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.